Business
Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells \n\t\t\tbody { font-size: 11pt;\n\t\t\t}\n\n\t\t\t.nr-sub-head ul,\n\t\t\t.nr-body ul {\n\t\t\t\tlist-style-type: disc !important;\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-sub-head ol,\n\t\t\t.nr-body ol {\n\t\t\t\tmargin-left: 2em !important;\n\t\t\t}\n\n\t\t\t.nr-body p, .nr-body {margin-bottom: 0px !important;\n\t\t\t\t\tmargin-top: 0px !important;\n\t\t\t\t\t-webkit-margin-before: 0px !important;\n\t\t\t\t\t-webkit-margin-after: 0px !important;\n\t\t\t\t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 11pt !important;\n\t\t\t }\n\n\t\t\ttbody {\n\t\t\t\tborder-top: 0;\n\t\t\t}\n\n\t\t\t H1 {font-weight: bold;\n\t\t\t\tfont-size: 16pt;\n\t\t\t }\n\n\t\t\t H2 {font-weight: bold;\n\t\t\t\tfont-size: 12pt;\n\t\t\t }\n\n\t\t\t H3 {font-weight: bold;\n\t\t\t\tfont-size: 11pt;\n\t\t\t }\n\n\n\t\t\t H1.nr-head {\n\t\t\t \t\tfont-family: Trebuchet MS !important;\n\t\t\t \t\tfont-size: 16pt !important;\n\t\t\t \t\tcolor: #3D86C6 !important;\n\t\t\t \t\tfont-weight:bold !important;\n\t\t\t \t\ttext-align:center !important;\n\n\t\t\t }\n\n\t\t\t H2.nr-sub-head {font-weight: bold !important;\n\t\t\t \t\tdisplay: block !important;\n\t\t\t \t\ttext-align: start !important;\n\t\t\t \t\tfont-family: Arial !important;\n\t\t\t\t\tfont-size: 12pt !important;\n\t\t\t }\n\n\t\t\t .nr-body a { font-size: 11pt !important;\n\t\t\t }\n\n\t\t\t TABLE { width: auto!important;\n\t\t\t }\n\n\t\t Theralase Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells\n Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations to safely and effectively destroy various cancers, announced today that its lead PDC, TLD-1433, combined with transferrin to form Rutherrin®, has been demonstrated to effectively destroy human brain cancer stem cells.\n\n \n\nDespite tremendous advances in cancer therapy over the last ten years, resistance to treatment and high rates of recurrence remain stubbornly common.\n\n \n\nIn fact, even patients who experience a complete cli...